Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture.
Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

Pharmaceuticals

Contamination by human and veterinary pharmaceutical derivatives refers to the undesirable presence of drug residues in the environment, including water, soil, and living organisms. This contamination can occur at various stages, including production, consumption, and disposal of medications. Main sources include releases from pharmaceutical facilities, wastewater discharges containing drug residues, and uncontrolled use of veterinary drugs in agriculture. Pharmaceutical contamination raises environmental and health concerns, impacting ecosystems and posing risks of antibiotic-resistant bacteria emergence. Conventional wastewater treatment methods may not efficiently remove these compounds, contributing to their persistence. Efforts are underway to develop advanced treatment technologies and sustainable pharmaceutical waste management practices. Regulations aim to limit releases and promote environmental monitoring to assess the extent of contamination by pharmaceutical derivatives.

IOXAGLIC ACID IMPURITY A CRS (20 MG)

IOXAGLIC ACID IMPURITY A CRS (20 MG)

22871-58-5

DISCOVER
MALIC ACID - REFERENCE SPECTRUM (N/A)

MALIC ACID - REFERENCE SPECTRUM (N/A)

NA

DISCOVER
MEBENDAZOLE FOR SYSTEM SUITABILITY CRS (20 MG)

MEBENDAZOLE FOR SYSTEM SUITABILITY CRS (20 MG)

31431-39-7

DISCOVER
METOPROLOL IMPURITY A CRS (15MG)

METOPROLOL IMPURITY A CRS (15MG)

NA

DISCOVER
NADOLOL CRS (100 MG)

NADOLOL CRS (100 MG)

42200-33-9

DISCOVER
PHENYLBUTAZONE IMPURITY B CRS(20 MG)

PHENYLBUTAZONE IMPURITY B CRS(20 MG)

NA

DISCOVER
RIFABUTIN CRS (150 MG)

RIFABUTIN CRS (150 MG)

72559-06-9

DISCOVER
TIANEPTINE SODIUM - REFERENCESPECTRUM (N/A)

TIANEPTINE SODIUM - REFERENCESPECTRUM (N/A)

NA

DISCOVER
SODIUM TIANEPTINE FOR SYSTEM SUITABILITY CRS (30 MG)

SODIUM TIANEPTINE FOR SYSTEM SUITABILITY CRS (30 MG)

30123-17-2

DISCOVER
TIANEPTINE IMPURITY A CRS (80MG)

TIANEPTINE IMPURITY A CRS (80MG)

29823-18-5

DISCOVER
TOLFENAMIC ACID CRS (100 MG)

TOLFENAMIC ACID CRS (100 MG)

13710-19-5

DISCOVER
TRAMADOL HYDROCHLORIDE CRS (50 MG)

TRAMADOL HYDROCHLORIDE CRS (50 MG)

36282-47-0

DISCOVER